? The IPM market is expected to be positive for Sun Pharma, Cipla, and Zydus Lifesciences. These companies from our coverage are expected to exhibit market beating or in line performance for Q4FY24E on the back of price increases and new product launches as well as growth in both chronic and acute segments.